Aegerion’s expans platform for development and global commercialization of therapies for cholesterol management.
Aegerion Pharmaceuticals in collaboration with Pfizer and the University of Pennsylvania entered into a cross-license relationship covering a range of patents related to the use of microsomal triglyceride transfer protein (MTP) inhibitors.

Based on the terms of the agreement, Aegerion can independently pursue product-development opportunities involving potential MTP-based therapies to reduce LDL cholesterol. MTP inhibitors have been proven effective in reducing LDL levels in men and women, according to the companies, and are being studied for potential use as monotherapies or in combination with statins or other therapies to reduce LDL cholesterol levels.

Previous articleAnorMED Board Reiterates Acceptance of Millennium Offer
Next articleValentis and Urigen to Merge